Account

Sign in to access your account and subscription

IP News

Highlights of the latest intellectual property news from around the country.

13 minute read April 01, 2005 at 11:19 AM
By
Eric Agovino
IP News

Federal Circuit Invalidates Fosamax Patent

In Merck & Co. v. Teva Pharms. USA, Inc., 395 F.3d 1364 (Fed. Cir. 2005), the Federal Circuit reversed a lower court's ruling, and found that claims 23 and 37 of U.S. Patent 5,994,329 (the '329 patent) were invalid for obviousness.

This premium content is locked for The Intellectual Property Strategist subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Intellectual Property Strategist

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

Adverse Possessor Provided Insufficient Evidence to Support TackingTown’s Installation of Guardrails Did Not Constitute a TakingMortgagee Entitled to Deficiency JudgmentLandowner Adequately Alleged Trespass During Renovation

September 01, 2026

How can legal teams move fast, reduce costs, and handle greater volumes of information? AI has rapidly become the de facto answer. But beneath the enthusiasm for AI, how are practitioners actually using AI-driven tools — and what are they learning as adoption shifts from experimentation to daily operations?

September 01, 2026

Notice of Pendency Provided Constructive Notice to Foreclosure Sale Purchaser

September 01, 2026